ATEC Reports Third Quarter Financial Results
Alphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ATEC Reports Third Quarter Financial Results Total revenue of $221 million, up 13% year-over-year Surgical revenue of $202 million increased 14% Case volumes grew 20% and net new surgeon users increased 25% CARLSBAD, Calif., October 29, 2026 – Alphatec Holdings, Inc.
How this was made
The 30-second read
Why it matters
The earnings miss and revised guidance may trigger short‑term sell pressure, but the growth in surgical hardware and surgeon adoption offers a potential upside catalyst.
Market read
Primary earnings disclosure for a niche medical device firm; relevance mainly to sector specialists and healthcare investors.
What to watch
Cash balance of $80M and positive free cash flow may provide runway for strategic investments.
Background
Alphatec Holdings is a Nasdaq‑listed spine‑focused medical device company that released its Q3 2026 earnings via an SEC 8‑K filing.
Ticker impact
Alphatec Holdings (ATEC) filed an 8‑K reporting Q3 2026 results and issued revised full‑year guidance.
likely pressure as the market prices in the guidance shortfall and modest earnings miss
The filing provides the first public disclosure of the quarter's numbers and updated guidance, which traders can act on immediately.
Market effects
Spine‑surgery device sector may see modest re‑rating as Alphatec signals slower biologics performance.
Limited to U.S. healthcare investors.
Low, confined to niche medical device market.
Counterpoint
Despite the shortfall, strong case‑volume growth and new surgeon adoption could support upside if biologics improve.
Key entities
- ExecutivePat Miles
Chairman and CEO of Alphatec, provided commentary on results.
- ExecutiveTommy Carls
New EVP of Data Intelligence & Strategy.
